Stem cells obtained from amniotic fluid, the umbilical cord (UC), and placenta are gaining in popularity. Stem cells from the umbilical cord offer several advantages, including: non-invasive collection procedures, more... These cells express low levels of major histo-compability complex (MHC) class I, and generally lack MHC class II and its co-stimulatory ligands like CD40, CD80, and CD86.
- Mechanism
- Curator reviewed
General theories of therapeutic action postulate that HUCMSCs can replace damaged cells, inhibit immunological functions through paracrine actions, and promote proliferation of endogenous stem cells through cell-cell communication. HUCMScs are thought to alter immune function through inhibition of Natural Killer Cell, T-cell, and B-cell proliferation along with redirecting monocytes and dendritic cells to less mature states. HUCMSCs are currently investigated for specific cell-based therapies, as they can be differentiated and engrafted for various disease states with low immunogenicity. Such applications include neurodegenerative diseases, spinal cord injury, stroke, and even liver disease. Certain factors secreted by HUCMSCs, such as oxidative stress pathways, are also thought to inhibit tumor growth and even lymphoma cell growth. These therapies are currently being considered for the treatment of COVID-19.
- Also known as
- hUCB-MSC · hUCB-MSCs · HUCMSCs · Human Umbilical Cord Wharton’s Jelly-derived Mesenchymal Stem Cells · Mesenchymal Stromal Cells
- Code names
- ACT-20
What you can answer from here — as of January 07, 2026
Which companies are running trials of Human Umbilical Cord Mesenchymal Stem Cells, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account